This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

inner_image_1920x170

NEWS & UPDATES

About adimore adimore

This author has not yet filled in any details.
So far adimore adimore has created 7 blog entries.

News & updates

By |December 30th, 2018|Uncategorized|

December 2018 ChemomAb appoints Bryan Jennings as Chief Financial Officer November  2018 ChemomAb to Present "CM101, A novel CCL24 blocking antibody, suppresses hepatic injury and fibrosis in  experimental models of NASH and liver fibrosis" at AASLD international Liver meeting in San Francisco 2018 October 2018 ChemomAb was granted an Orphan Drug Designation from the FDA [...]

Comments Off on News & updates

NASH and PSC

By |October 18th, 2017|About us|

Scott L. Friedman MD, Icahn School of Medicine at Mount Sinai hospital, New York, USA Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai.  His pioneering research in hepatic fibrosis supported by NIH since 1986, combined with mentoring of over 80 trainees have [...]

Comments Off on NASH and PSC

News & updates

By |February 28th, 2016|Uncategorized|

April 2019 ChemomAb doses first subject in a phase 1 clinical trial of Subcutaneous injected CM-101 in healthy volunteers April 2019 ChemomAb to present “Attenuation of CCL24, using CM-101- a Novel monoclonal antibody, reduces cholangiocytes proliferation in experimental cholestasis models” at EASL International Liver Congress 2019. ILC_2019_ final   ChemomAb Doses First Patient in Phase [...]

Comments Off on News & updates

Board of Directors

By |February 28th, 2016|Uncategorized|

Stephen Squinto, Chairman of the Board Stephen Squinto is a Venture Partner with OrbiMed who brings over 25 years of experience in the biotechnology industry. Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head [...]

Comments Off on Board of Directors

Our Team

By |February 28th, 2016|About us, Uncategorized|

Dr. Adi Mor, CEO and CSO ChemomAb is managed by Dr. Mor, who co-founded the company in 2011. Dr. Mor has extensive knowledge and experience in the fields of immunology, autoimmune and inflammatory diseases and a wide experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and cancer diseases. [...]

Comments Off on Our Team

About Us

By |February 28th, 2016|Uncategorized|

ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has [...]

Comments Off on About Us

Contact us

By |February 4th, 2016|Uncategorized|

ChemomAb Ltd. Kiryat Atidim, Building 7, Entrance 2 Tel Aviv Israel 6158002  

Comments Off on Contact us